Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 36 of 728 for:    Area Under Curve AND Bioavailability

Bioavailability Study Of PF-06651600 In Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02684760
Recruitment Status : Completed
First Posted : February 18, 2016
Last Update Posted : June 16, 2016
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
PF-06651600 is being developed for treatment of inflammatory bowel disease. This study will test the bioavailability of a solid dose formulation of PF-06651600 compared to an oral solution formulation under fasting conditions and the effect of a high fat meal on the bioavailability of the solid dose formulation of PF-06651600 in healthy subjects. Safety and tolerability of the tablet and oral solution formulations of PF-06651600 will be assessed under fasting and fed conditions.

Condition or disease Intervention/treatment Phase
Healthy Drug: PF-06651600 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1, Open Label, Single-dose 3-way Crossover Study To Evaluate The Relative Bioavailability Of A Solid Dose Formulation Of Pf-06651600 Under Fasting Conditions And The Effect Of A High Fat Meal On The Bioavailability Of The Solid Dosage Formulation Of Pf-06651600 In Healthy Subjects
Study Start Date : February 2016
Actual Primary Completion Date : May 2016
Actual Study Completion Date : May 2016

Arm Intervention/treatment
Experimental: Cohort 1: PF-06651600
Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
Drug: PF-06651600
PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.

Experimental: Cohort 2: PF-06651600
Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
Drug: PF-06651600
PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.

Experimental: Cohort 3: PF-06651600
Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
Drug: PF-06651600
PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.

Experimental: Cohort 4: PF-06651600
Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
Drug: PF-06651600
PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.

Experimental: Cohort 5: PF-06651600
Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
Drug: PF-06651600
PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.

Experimental: Cohort 6: PF-06651600
Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
Drug: PF-06651600
PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.




Primary Outcome Measures :
  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-06651600 [ Time Frame: 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose ]
    Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)

  2. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06651600 [ Time Frame: 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose ]
    Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

  3. Time to Reach Maximum Observed Plasma Concentration (Cmax) for PF-06651600 [ Time Frame: 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose ]
    Time to Reach Maximum Observed Plasma Concentration (Cmax)


Secondary Outcome Measures :
  1. Plasma Decay Half Life (t1/2) for PF-06651600 [ Time Frame: 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose ]
    Plasma Decay Half-Life (t1/2)

  2. Time to Reach Maximum Concentration (Tmax) for PF-06651600 [ Time Frame: 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose ]
    Time to Reach Maximum Concentration (Tmax)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male/female subjects between 18 and 55 years old, inclusive. Females must be of non-child bearing potential.
  • BMI of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
  • Prior history of chicken pox.
  • Evidence of personally signed and dated informed consent document.
  • Willing and able to comply with scheduled visits, treatment plan, lab tests and other study procedures.

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, GI, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
  • History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males.
  • Screening blood pressure >140/90 mm Hg.
  • Screening laboratory abnormalities as defined by the protocol.
  • Unwilling or unable to comply with the Lifestyle Guidelines as defined by the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02684760


Locations
Layout table for location information
Belgium
Pfizer Clinical Research Unit
Brussels, Belgium, 1070
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT02684760     History of Changes
Other Study ID Numbers: B7981003
2015-004857-41 ( EudraCT Number )
First Posted: February 18, 2016    Key Record Dates
Last Update Posted: June 16, 2016
Last Verified: June 2016
Keywords provided by Pfizer:
Inflammatory Bowel Disease